Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
24.94+0.50 (+2.05%)
At close: 04:00PM EDT
24.94 0.00 (0.00%)
After hours: 04:03PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.50B
Enterprise value 3.00B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.72
Enterprise value/revenue N/A
Enterprise value/EBITDA -12.57

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 373.19%
S&P500 52-week change 3-7.05%
52-week high 346.16
52-week low 312.01
50-day moving average 330.73
200-day moving average 331.56

Share statistics

Avg vol (3-month) 3433.64k
Avg vol (10-day) 3666.25k
Shares outstanding 5148.29M
Implied shares outstanding 6N/A
Float 860.11M
% held by insiders 118.57%
% held by institutions 182.85%
Shares short (28 Apr 2022) 44.48M
Short ratio (28 Apr 2022) 414.41
Short % of float (28 Apr 2022) 411.68%
Short % of shares outstanding (28 Apr 2022) 43.02%
Shares short (prior month 30 Mar 2022) 44.7M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.43%
Return on equity (ttm)-56.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -237.97M
Net income avi to common (ttm)-242.65M
Diluted EPS (ttm)-1.71
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)542.94M
Total cash per share (mrq)3.66
Total debt (mrq)64.3M
Total debt/equity (mrq)12.33
Current ratio (mrq)15.67
Book value per share (mrq)3.52

Cash flow statement

Operating cash flow (ttm)-209.78M
Levered free cash flow (ttm)-132.33M